{
    "title": "IoM July 2009 Table of Contents",
    "slug": "iom-july-2009-table-of-contents",
    "aliases": [
        "/IoM+July+2009+Table+of+Contents",
        "/57"
    ],
    "tiki_page_id": 57,
    "date": "2010-04-02",
    "categories": [
        "Deficiency of Vitamin D",
        "Toxicity of Vitamin D"
    ],
    "tags": [
        "Deficiency of Vitamin D",
        "Toxicity of Vitamin D",
        "bone",
        "bone cancer",
        "bone mineral density",
        "bone stress fractures",
        "breast cancer",
        "cancer",
        "cardiovascular",
        "child",
        "childhood cancer",
        "colon cancer",
        "diabetes",
        "falls fractures",
        "hypertension",
        "life span",
        "metabolic",
        "mortality",
        "pancreatic cancer",
        "preeclampsia",
        "pregnancy",
        "preterm",
        "prostate cancer",
        "rickets",
        "stroke",
        "vitamin d",
        "vitamin d blood test"
    ]
}


<p>

<font style="font-family:'Times New Roman';font-size:12pt;letter-spacing:-.2pt;"><b><i>Evidence Report/Technology Assessment  </i></b></font><font style="font-family:Arial;font-size:14pt;letter-spacing:0pt;"><b>Number 183</b></font></p>

<p style="margin-top:55.8pt;">

<font style="font-family:Arial;font-size:18pt;letter-spacing:-.6pt;"><b>Vitamin D and Calcium: A Systematic Review of </b></font><font style="font-family:Arial;font-size:18pt;letter-spacing:0pt;"><b>Health Outcomes</b></font></p>

<p style="margin-top:28.8pt;">

<font style="letter-spacing:-.3pt;"><b>Prepared for:</b></font></p>

<p style="margin-right:2.45in;">

<font style="letter-spacing:-.1pt;">Agency for Healthcare Research and Quality </font><font style="letter-spacing:-.4pt;">U.S. Department of Health and Human Services </font><font style="letter-spacing:-.3pt;">540 Gaither Road</font></p>

<p>

<font style="letter-spacing:-.1pt;">Rockville, MD 20850</font></p>

<p>

<a href="http://www.ahrq.gov/" style="color:rgb(0,0,255);"><font style="color:rgb(0,0,255);letter-spacing:-.4pt;"><u>www.ahrq.gov</u></font></a><font style="letter-spacing:-.4pt;"> </font></p>

<p style="margin-right:2.95in;margin-top:14.4pt;">

<font style="letter-spacing:-.5pt;"><b>Contract No. HHSA 290-2007-10055-I </b></font><font style="letter-spacing:-.3pt;"><b>Task Order No. 4</b></font></p>

<p style="margin-top:14.4pt;">

<font style="letter-spacing:0pt;"><b>Prepared by</b></font><font style="letter-spacing:0pt;">:   </font>Tufts Evidence-based Practice Center, Boston, MA</p>

<p style="margin-top:19.8pt;">

<i>Investigators:</i></p>

<p>

<font style="letter-spacing:-.3pt;">Mei Chung, M.P.H.</font></p>

<p style="margin-right:3.75in;">

<font style="letter-spacing:-.5pt;">Ethan M Balk, M.D., M.P.H. </font>Michael Brendel, B.A.</p>

<p style="margin-top:1.8pt;">

<font style="letter-spacing:-.3pt;">Stanley Ip, M.D.</font></p>

<p>

<font style="letter-spacing:-.3pt;">Joseph Lau, M.D.</font></p>

<p>

<font style="letter-spacing:-.3pt;">Jounghee Lee, Ph.D.</font></p>

<p style="margin-right:3.7in;">

<font style="letter-spacing:0pt;">Alice Lichtenstein, D.Sc. </font><font style="letter-spacing:-.5pt;">Kamal Patel, M.B.A., M.P.H. </font><font style="letter-spacing:-.3pt;">Gowri Raman, M.D.</font></p>

<p style="margin-right:3.75in;">

<font style="letter-spacing:-.5pt;">Athina Tatsioni, M.D., Ph.D. </font><font style="letter-spacing:-.3pt;">Teruhiko Terasawa, M.D.</font></p>

<p>

Thomas A Trikalinos, M.D., Ph.D.</p>

<p style="margin-right:3.4in;margin-top:54pt;">

<font style="letter-spacing:-.5pt;"><b>AHRQ Publication No. 09-E015 </b></font><font style="letter-spacing:0pt;"><b>August 2009</b></font></p>

<p>

<font style="letter-spacing:0pt;"><b><font style="letter-spacing:0pt;"> </font></b></font></p>

<p style="margin-left:.1in;">

<font style="letter-spacing:-.3pt;">This document is in the public domain and may be used and reprinted without permission except </font><font style="letter-spacing:-.1pt;">those copyrighted materials noted for which further reproduction is prohibited without the </font>specific permission of copyright holders.<br /><font style="letter-spacing:-.2pt;"><b> </b></font></p>

<p style="margin-left:.1in;">

<font style="letter-spacing:-.2pt;"><b>Outcomes. </b></font><font style="letter-spacing:-.2pt;">Evidence Report No. 183. (Prepared by the Tufts Evidence-based Practice Center </font><font style="letter-spacing:-.5pt;">under Contract No. HHSA 290-2007-10055-I.) AHRQ Publication No. 09-E015. Rockville, MD: </font>Agency for Healthcare Research and Quality. August, 2009.</p>

<p>

<font style="font-family:Arial;font-size:18pt;"><b><font style="letter-spacing:0pt;"> </font></b></font></p>

<p>

<b>Preface</b></p>

<p style="text-indent:.3in;margin-left:0in;margin-right:.05in;margin-top:23.4pt;">

<font style="letter-spacing:-.1pt;">The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based </font><font style="letter-spacing:-.1pt;">Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public- and private-sector organizations in their efforts to improve the </font>quality of health care in the United States. The Office of Dietary Supplements/National Institutes <font style="letter-spacing:-.1pt;">of Health, the Public Health Agency of Canada, Health Canada, and Food and Drug Administration requested and provided funding for this report. The reports and assessments </font><font style="letter-spacing:0pt;">provide organizations with comprehensive, science-based information on common, costly </font><font style="letter-spacing:-.1pt;">medical conditions and new health care technologies. The EPCs systematically review the </font><font style="letter-spacing:0pt;">relevant scientific literature on topics assigned to them by AHRQ and conduct additional </font>analyses when appropriate prior to developing their reports and assessments.</p>

<p style="text-indent:.3in;margin-left:0in;margin-right:.05in;margin-top:1.8pt;">

<font style="letter-spacing:-.3pt;">To bring the broadest range of experts into the development of evidence reports and health </font>technology assessments, AHRQ encourages the EPCs to form partnerships and enter into <font style="letter-spacing:-.4pt;">collaborations with other medical and research organizations. The EPCs work with these partner </font><font style="letter-spacing:-.3pt;">organizations to ensure that the evidence reports and technology assessments they produce will </font><font style="letter-spacing:-.3pt;">become building blocks for health care quality improvement projects throughout the Nation. The </font>reports undergo peer review prior to their release.</p>

<p style="text-indent:.25in;margin-left:0in;margin-right:.05in;">

<font style="letter-spacing:-.1pt;">AHRQ expects that the EPC evidence reports and technology assessments will inform </font><font style="letter-spacing:-.4pt;">individual health plans, providers, and purchasers as well as the health care system as a whole by </font>providing important information to help improve health care quality.</p>

<p style="text-indent:.25in;margin-left:0in;margin-right:.05in;">

<font style="letter-spacing:-.4pt;">We welcome comments on this evidence report. They may be sent by mail to the Task Order </font><font style="letter-spacing:-.1pt;">Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, </font><font style="letter-spacing:-.3pt;">Rockville, MD 20850, or by email to</font><font style="letter-spacing:-.3pt;"><b> </b></font><a href="mailto:epc@ahrq.gov" style="color:rgb(0,0,255);"><font style="color:rgb(0,0,255);letter-spacing:-.3pt;"><b><u>epc@ahrq.gov</u></b></font></a><font style="letter-spacing:-.3pt;"><b>.</b></font></p>

<p style="margin-top:28.8pt;">

<font style="letter-spacing:-.5pt;">Carolyn M. Clancy, M.D.                                            </font>Jean Slutsky, P.A., M.S.P.H.</p>

<p>

<font style="letter-spacing:-.6pt;">Director                                                                       </font>Director, Center for Outcomes and Evidence</p>

<p>

<font style="letter-spacing:-.5pt;">Agency for Healthcare Research and Quality              </font>Agency for Healthcare Research and Quality</p>

<p style="margin-top:27pt;">

<font style="letter-spacing:-.4pt;">Beth A. Collins Sharp, R.N., Ph.D.                              </font><font style="letter-spacing:-.3pt;">Stephanie Chang, M.D., M.P.H.</font></p>

<p style="margin-top:1.8pt;">

<font style="letter-spacing:-.6pt;">Director, EPC Program                                                 </font>EPC Program Task Order Officer</p>

<p>

<font style="letter-spacing:-.5pt;">Agency for Healthcare Research and Quality              </font>Agency for Healthcare Research and Quality</p>

<p style="margin-top:27pt;">

<font style="letter-spacing:-.6pt;">Paul M. Coates, Ph.D.                                                  </font>Elizabeth A. Yetley, Ph.D.</p>

<p>

<font style="letter-spacing:-.4pt;">Director, Office of Dietary Supplements                     </font>Senior Nutrition Research Scientist, Retired</p>

<p>

<font style="letter-spacing:-.5pt;">National Institutes of Health                                         </font>Office of Dietary Supplements</p>

<p style="margin-left:3.5in;">

</p>

<p style="margin-left:.05in;">

<font style="letter-spacing:-.5pt;">Mary Frances Picciano, Ph.D.                                       </font>Kimberly D. Elmslie, M.Sc.</p>

<p style="margin-left:.05in;">

Senior Nutrition Research Scientist                               Director General</p>

<p style="margin-left:.15in;">

<font style="letter-spacing:-.5pt;">Office of Dietary Supplements                                    </font>Centre for Chronic Disease Prevention and</p>

<p style="margin-left:.05in;">

<font style="letter-spacing:-.4pt;">National Institutes of Health                                           </font><font style="letter-spacing:0pt;">Control  </font>Public Health Agency of Canada</p>

<p style="margin-left:.05in;margin-top:14.4pt;">

<font style="letter-spacing:-.6pt;">Margaret de Groh, Ph.D.                                                </font>Hasan Hutchinson, Ph.D., N.D.</p>

<p style="margin-left:.05in;">

<font style="letter-spacing:-.5pt;">Manager, Risk Factors Unit                                           </font>Director General</p>

<p style="margin-left:.05in;margin-right:.2in;">

<font style="letter-spacing:-.3pt;">Centre for Chronic Disease Prevention and Control Office of Nutrition Policy and Promotion Health Canada     </font>Public Health Agency of Canada</p>

<p style="margin-left:.05in;margin-top:12.6pt;">

<font style="letter-spacing:-.4pt;">Linda Greene-Finestone, Ph.D., R.D.                           </font>Paula R. Trumbo, Ph.D.</p>

<p style="margin-left:.05in;">

<font style="letter-spacing:-.5pt;">Nutrition Advisor                                                          </font>Supervisor, Nutrition Science Evaluation</p>

<p style="margin-left:.05in;margin-right:.2in;">

<font style="letter-spacing:-.3pt;">Centre for Chronic Disease Prevention and Control Office of Nutrition, Labeling and Dietary </font><font style="letter-spacing:-.4pt;">Public Health Agency of Canada    </font><font style="letter-spacing:0pt;">Supplements</font></p>

<p style="margin-left:3.65in;margin-right:.55in;">

<font style="letter-spacing:-.5pt;">Center for Food Safety and Applied </font><font style="letter-spacing:0pt;">Nutrition</font></p>

<p style="margin-left:3.65in;">

Food and Drug Administration</p>

<p>

<font style="letter-spacing:0pt;"> </font></p>

<p style="margin-left:.05in;">

<font style="font-family:Arial;font-size:18pt;letter-spacing:0pt;"><b>Acknowledgments</b></font></p>

<p style="text-indent:.25in;margin:18pt .15in 14.4pt .05in;">

<font style="letter-spacing:-.4pt;">We would like to acknowledge with appreciation the following members of the Technical </font>Expert Panel for their advice and consultation to the Tufts Evidence-based Practice Center during the preparation for this report:</p>

<p>

<font style="letter-spacing:0pt;"> </font></p>

<p style="margin-left:.05in;">

<font style="letter-spacing:-.3pt;">Steven Abrams, M.D.</font></p>

<p style="margin-left:.05in;">

<font style="letter-spacing:-.4pt;">Baylor College of Medicine </font><font style="letter-spacing:0pt;">Section of Neonatology </font>Texas Children's Hospital Houston, Texas</p>

<p style="margin-left:.05in;margin-top:14.4pt;">

<font style="letter-spacing:-.3pt;">Stephanie Atkinson, Ph.D.</font></p>

<p style="margin-left:.05in;margin-right:.8in;">

<font style="letter-spacing:-.4pt;">Professor and Associate Chair </font>Department of Pediatrics</p>

<p style="margin-left:.05in;margin-right:.2in;">

<font style="letter-spacing:-.4pt;">Biochemistry and Biomedical Sciences </font>Health Sciences</p>

<p style="margin-left:.05in;">

McMaster University</p>

<p style="margin-left:.05in;">

Hamilton, Canada</p>

<p style="margin-left:.05in;margin-top:12.6pt;">

Patsy M. Brannon, Ph.D.</p>

<p style="margin-left:.05in;">

Professor</p>

<p style="margin-left:.05in;margin-right:.65in;margin-top:3.6pt;">

<font style="letter-spacing:-.4pt;">Division of Nutritional Sciences </font>Cornell University</p>

<p style="margin-left:.05in;">

Ithaca, New York</p>

<p style="margin-left:.05in;margin-right:1.05in;margin-top:12.6pt;">

<font style="letter-spacing:-.5pt;">Rebecca D. Jackson, M.D. </font>Associate Professor</p>

<p style="margin-left:.05in;">

Department of Internal Medicine</p>

<p style="margin-left:.05in;margin-right:.05in;">

<font style="letter-spacing:-.5pt;">Division of Endocrinology, Diabetes, and </font><font style="letter-spacing:0pt;">Metabolism</font></p>

<p style="margin-left:.05in;margin-right:1.05in;">

<font style="letter-spacing:-.4pt;">The Ohio State University </font><font style="letter-spacing:-.3pt;">Columbus, Ohio</font></p>

<p style="line-height:13.7pt;">

<br />

Glenville Jones, Ph.D.</p>

<p style="line-height:11.8pt;">

Professor and Head</p>

<p style="line-height:13.9pt;margin-right:.95in;">

<font style="letter-spacing:-.4pt;">Department of Biochemistry </font>Queen's University</p>

<p style="line-height:13.5pt;">

Ontario, Canada</p>

<p style="line-height:12.7pt;margin-right:.35in;margin-top:18pt;">

<font style="letter-spacing:-.5pt;">Susan Taylor Mayne, Ph.D., F.A.C.E. </font><font style="letter-spacing:0pt;">Professor</font></p>

<p style="line-height:12.8pt;">

<font style="letter-spacing:-.5pt;">Division of Chronic Disease Epidemiology </font>Yale School of Public Health</p>

<p style="line-height:13.7pt;">

New Haven, Connecticut</p>

<p style="line-height:13.7pt;margin-top:27pt;">

Clifford J. Rosen, M.D.</p>

<p style="line-height:11.8pt;">

Senior Scientist</p>

<p style="line-height:13.9pt;margin-right:.15in;margin-top:1.8pt;">

<font style="letter-spacing:-.5pt;">Maine Medical Center Research Institute </font><font style="letter-spacing:-.3pt;">Scarborough, Maine</font></p>

<p>

<font style="letter-spacing:-.3pt;"><font style="letter-spacing:0pt;"> </font></font></p>

<p style="margin-left:.05in;">

<b>Structured Abstract</b></p>

<p style="margin-left:.05in;margin-right:.1in;margin-top:10.8pt;">

<font style="letter-spacing:-.3pt;"><b>Background</b></font><font style="letter-spacing:-.3pt;">: Since the 1997 Dietary Reference Intake (DRI) values for vitamin D and calcium </font><font style="letter-spacing:-.3pt;">were established new data have become available on their relationship, both individually and </font><font style="letter-spacing:-.2pt;">combined, to a wide range of health outcomes. The Institute of Medicine/Food and Nutrition </font>Board has constituted a DRI committee to undertake a review of the evidence and potential <font style="letter-spacing:-.3pt;">revision of the current DRI values for these nutrients. To support this review, several US and </font><font style="letter-spacing:-.2pt;">Canadian federal government agencies commissioned a systematic review of the scientific </font><font style="letter-spacing:-.4pt;">literature for use during the deliberations by the committee. The intent of providing a systematic </font><font style="letter-spacing:-.5pt;">review to the committee is to support transparency of the literature review process and provide a </font>foundation for subsequent reviews of the nutrients.</p>

<p style="margin-left:.05in;margin-right:.05in;margin-top:16.2pt;">

<b>Purpose: </b>To systematically summarize the evidence on the relationship between vitamin D, <font style="letter-spacing:-.3pt;">calcium, and a combination of both nutrients on a wide range of health outcomes as identified by </font>the IOM, AHRQ and technical expert panel convened to support the project.</p>

<p style="margin-left:.05in;margin-right:.25in;margin-top:12.6pt;">

<font style="letter-spacing:-.3pt;"><b>Data sources</b></font><font style="letter-spacing:-.3pt;">: MEDLINE; Cochrane Central; Cochrane Database of Systematic Reviews; and </font>the Health Technology Assessments; search limited to English-language articles in humans.</p>

<p style="margin-left:.05in;margin-right:.1in;margin-top:14.4pt;">

<font style="letter-spacing:-.1pt;"><b>Study selection</b></font><font style="letter-spacing:-.1pt;">: Primary interventional or observational studies that reported outcomes of </font><font style="letter-spacing:-.3pt;">interest in human subjects in relation to vitamin D and/or calcium, as well as systematic reviews </font><font style="letter-spacing:-.1pt;">that met the inclusion and exclusion criteria. Cross sectional and retrospective case-control </font>studies were excluded.</p>

<p style="margin-left:.05in;margin-right:.1in;margin-top:14.4pt;">

<font style="letter-spacing:-.3pt;"><b>Data extraction</b></font><font style="letter-spacing:-.3pt;">: A standardized protocol with predefined criteria was used to extract details on </font>study design, interventions, outcomes, and study quality.</p>

<p style="margin-left:.05in;margin-right:.05in;margin-top:14.4pt;">

<font style="letter-spacing:0pt;"><b>Data synthesis</b></font><font style="letter-spacing:0pt;">: We summarized 165 primary articles and 11 systematic reviews that </font>incorporated over 200 additional primary articles. Available evidence focused mainly on bone <font style="letter-spacing:-.3pt;">health, cardiovascular diseases or cancer outcomes. For many outcomes, it was difficult to draw </font><font style="letter-spacing:-.1pt;">firm conclusions on the basis of the available literature concerning the association of either </font><font style="letter-spacing:-.3pt;">serum 25(OH)D concentration or calcium intake, or the combination of both nutrients. Findings </font><font style="letter-spacing:-.1pt;">were inconsistent across studies for colorectal and prostate cancer, and pregnancy-related </font>outcomes including preeclampsia. There were few studies for pancreatic cancer and immune <font style="letter-spacing:-.4pt;">function. Among trials of hypertensive adults, calcium supplementation lowered systolic, but not </font><font style="letter-spacing:-.5pt;">diastolic, blood pressure by 2-4 mm Hg. For body weight, the trials were consistent in finding no </font><font style="letter-spacing:-.1pt;">significant effect of increased calcium intake on weight. For growth rates, a meta-analysis did </font><font style="letter-spacing:-.1pt;">not find a significant effect on weight or height gain attributable to calcium supplement in </font><font style="letter-spacing:-.2pt;">children. For bone health, one systematic review found that vitamin D plus calcium </font><font style="letter-spacing:-.1pt;">supplementation resulted in small increases in BMD of the spine and other areas in </font>postmenopausal women. For breast cancer, calcium intakes in premenopausal women were associated with a decreased risk. For prostate cancer, some studies reported that high calcium intakes were associated with an increased risk.</p>

<p style="margin-left:.05in;margin-right:.1in;margin-top:12.6pt;">

<font style="letter-spacing:-.1pt;"><b>Limitations</b></font><font style="letter-spacing:-.1pt;">: Studies on vitamin D and calcium were not specifically targeted at life stages </font><font style="letter-spacing:-.3pt;">(except for pregnant and postmenopausal women) specified for the determination of DRI. There</font></p>

<p>

<font style="letter-spacing:-.3pt;"><font style="letter-spacing:0pt;"> </font></font></p>

<p style="margin-left:.1in;margin-right:.1in;">

<font style="letter-spacing:-.4pt;">is large variation on the methodological quality of studies examined. Use of existing systematic </font>reviews limits analyses that could be performed on this source of information.</p>

<p style="margin-left:.1in;margin-right:.1in;margin-top:9pt;">

<font style="letter-spacing:-.3pt;"><b>Conclusions</b></font><font style="letter-spacing:-.3pt;">: The majority of the findings concerning vitamin D, calcium, or a combination of </font><font style="letter-spacing:-.4pt;">both nutrients on the different health outcomes were inconsistent. Synthesizing a dose-response </font>relation between intake of either vitamin D, calcium, or both nutrients and health outcomes in this heterogeneous body of literature prove challenging.</p>

<p>

<font style="letter-spacing:0pt;"> </font></p>

<p style="margin-left:.05in;">

<b>Contents</b></p>

<p style="margin-left:.05in;margin-top:10.8pt;">

Executive Summary</p>

<p style="margin-left:.05in;margin-top:14.4pt;">

<b>Evidence Report..........................................................................................................................</b><font style="letter-spacing:0pt;"><b>15</b></font></p>

<p style="margin-left:.05in;margin-top:14.4pt;">

Chapter 1. Introduction</p>

<p style="margin-left:.2in;">

<font style="letter-spacing:0pt;">Background</font></p>

<p style="margin-left:.2in;margin-right:3.15in;">

<font style="letter-spacing:-.5pt;">Sources, metabolism and functions of vitamin D</font><font style="letter-spacing:-.5pt;"> </font>Sources, metabolism and functions of calcium Challenges for the DRI committees</p>

<p style="margin-left:.2in;">

Key Questions addressed in this report</p>

<p style="margin-left:.05in;margin-top:14.4pt;">

Chapter 2. Methods</p>

<p style="margin-left:.2in;">

<font style="letter-spacing:0pt;">Overview</font></p>

<p style="margin-left:.55in;">

Sponsoring Federal agencies</p>

<p style="margin-left:.5in;">

AHRQ Task Order Officer (TOO)</p>

<p style="margin-left:.55in;">

Technical Expert Panel (TEP)</p>

<p style="margin-left:.55in;">

EPC methodologists</p>

<p style="margin-left:.2in;">

Development of the analytic framework and refinement of key questions</p>

<p style="margin-left:.2in;">

<font style="letter-spacing:0pt;">Definitions</font></p>

<p style="margin-left:.35in;margin-top:1.8pt;">

Vitamin D and calcium exposures</p>

<p style="margin-left:.35in;">

Clinical outcomes</p>

<p style="margin-left:.35in;">

Indicators of exposure (nutrient intake)</p>

<p style="margin-left:.35in;margin-right:4.7in;">

<font style="letter-spacing:0pt;">Surrogate outcomes</font><font style="letter-spacing:0pt;"> </font><font style="letter-spacing:-.5pt;">Intermediate outcomes</font><font style="letter-spacing:-.5pt;"> </font><font style="letter-spacing:0pt;">Life stages</font></p>

<p style="margin-left:.2in;">

Key questions</p>

<p style="margin-left:.2in;margin-right:4.7in;">

<font style="letter-spacing:-.5pt;">Literature search strategy</font><font style="letter-spacing:-.5pt;"> </font>Study selection</p>

<p style="margin-left:.35in;">

Abstract screening</p>

<p style="margin-left:.35in;">

Full text article eligibility criteria</p>

<p style="margin-left:.5in;margin-top:1.8pt;">

Primary studies</p>

<p style="margin-left:.55in;">

Systematic reviews</p>

<p style="margin-left:.35in;">

Other specific eligibility criteria</p>

<p style="margin-left:.35in;">

Data analysis</p>

<p style="margin-left:.2in;">

Meta-analysis</p>

<p style="margin-left:.2in;">

Grading of studies analyzed in this evidence report</p>

<p style="margin-left:.2in;">

Critical appraisal and grading of primary studies</p>

<p style="margin-left:.35in;">

Additional considerations of methodological quality of primary studies for the</p>

<p style="margin-left:.35in;">

purpose of DRI decision making</p>

<p style="margin-left:.2in;">

Critical appraisal of systematic reviews</p>

<p style="text-align:center;">

Reporting of the evidence<br />

Evidence tables</p>

<p style="text-align:center;">

<font style="letter-spacing:-.3pt;">Summary tables</font></p>

<p>

<font style="letter-spacing:-.3pt;"><font style="letter-spacing:0pt;"> </font></font></p>

<p style="margin-left:.45in;margin-right:.4in;">

<font style="letter-spacing:-.4pt;">Graphical presentation of dose-response relationship</font><font style="letter-spacing:-.4pt;"> </font>Grand summary tables (evidence map)</p>

<p style="margin-left:.45in;">

<font style="letter-spacing:0pt;">Assay method</font></p>

<p style="margin-left:.45in;">

<font style="letter-spacing:-.3pt;">Sunlight exposure</font></p>

<p style="margin-left:.45in;">

Primary and secondary outcomes</p>

<p style="margin-left:.45in;">

Study quality</p>

<p style="margin-left:.45in;">

<font style="letter-spacing:-.3pt;">Organization of the Results Section</font></p>

<p style="margin-top:14.4pt;">

Chapter 3. Results</p>

<p style="margin-left:.15in;margin-right:2.1in;">

<font style="letter-spacing:0pt;">Literature search results</font><font style="letter-spacing:0pt;"> </font><font style="letter-spacing:-.4pt;">Vitamin D and health outcomes</font></p>

<p style="margin-left:.3in;">

Vitamin D and growth</p>

<p style="margin-left:.3in;">

<font style="letter-spacing:-.3pt;">Vitamin D and cardiovascular disease</font></p>

<p style="margin-left:.3in;">

Vitamin D and body weight</p>

<p style="margin-left:.3in;">

Vitamin D and cancer</p>

<p style="margin-left:.45in;margin-top:1.8pt;">

Cancer from all causes and total cancer mortality</p>

<p style="margin-left:.45in;margin-right:2.55in;">

<font style="letter-spacing:0pt;">Prostate cancer</font><font style="letter-spacing:0pt;"> </font><font style="letter-spacing:0pt;">Colorectal cancer</font><font style="letter-spacing:0pt;"> </font>Colorectal adenoma Breast cancer</p>

<p style="margin-left:.45in;">

Pancreatic cancer</p>

<p style="margin-left:.3in;">

Vitamin D and immunologic outcomes</p>

<p style="margin-left:.3in;">

<font style="letter-spacing:-.3pt;">Vitamin D and pregnancy-related outcomes</font></p>

<p style="margin-left:.45in;">

<font style="letter-spacing:0pt;">Preeclampsia</font></p>

<p style="margin-left:.45in;">

Other outcomes</p>

<p style="margin-left:.3in;">

Vitamin D and clinical outcomes of bone health</p>

<p style="margin-left:.45in;">

<font style="letter-spacing:0pt;">Rickets</font></p>

<p style="margin-left:.45in;">

Fractures, falls, or performance measures</p>

<p style="margin-left:.3in;">

Vitamin D and all-cause mortality</p>

<p style="text-indent:-.15in;margin-left:.45in;margin-right:.85in;">

<font style="letter-spacing:-.4pt;">Vitamin D and hypertension and blood pressure </font><font style="letter-spacing:0pt;">Hypertension</font></p>

<p style="margin-left:.45in;">

Vitamin D and blood pressure</p>

<p style="text-indent:.15in;margin-left:.15in;">

<font style="letter-spacing:-.4pt;">Vitamin D and bone mineral density or bone mineral content</font><font style="letter-spacing:-.4pt;"> </font>Calcium and health outcomes</p>

<p style="margin-left:.3in;">

Calcium and growth</p>

<p style="margin-left:.3in;">

Calcium and cardiovascular disease</p>

<p style="margin-left:.3in;">

Calcium and body weight</p>

<p style="margin-left:.3in;">

Calcium and cancer</p>

<p style="margin-left:.45in;margin-top:1.8pt;">

Cancer from all cause and total cancer mortality</p>

<p style="margin-left:.45in;margin-right:2.3in;">

<font style="letter-spacing:0pt;">Prostate cancer</font><font style="letter-spacing:0pt;"> </font><font style="letter-spacing:0pt;">Colorectal cancer</font><font style="letter-spacing:0pt;"> </font><font style="letter-spacing:0pt;">Colorectal adenoma</font><font style="letter-spacing:0pt;"> </font><font style="letter-spacing:-.3pt;">Breast cancer incidence</font></p>

<p style="margin-left:.45in;">

Breast Mammographic Density</p>

<p style="margin-left:.45in;">

</p>

<p style="margin-left:.3in;">

<font style="letter-spacing:-.3pt;">Calcium and pregnancy-related outcomes</font></p>

<p style="margin-left:.45in;">

<font style="letter-spacing:0pt;">Preeclampsia</font></p>

<p style="margin-left:.45in;">

High blood pressure with or without proteinuria during pregnancy</p>

<p style="margin-left:.45in;">

Small for gestational age infant</p>

<p style="margin-left:.3in;">

Calcium and all-cause mortality</p>

<p style="margin-left:.3in;">

Calcium and hypertension and blood pressure</p>

<p style="margin-left:.5in;">

Calcium and hypertension</p>

<p style="margin-left:.5in;">

Calcium and blood pressure</p>

<p style="margin-left:.15in;">

<font style="letter-spacing:-.3pt;">Combined vitamin D and calcium and health outcomes</font></p>

<p style="margin-left:.3in;margin-top:1.8pt;">

Combined vitamin D calcium and growth</p>

<p style="margin-left:.3in;">

<font style="letter-spacing:-.3pt;">Combined vitamin D and calcium and body weight</font></p>

<p style="margin-left:.3in;">

<font style="letter-spacing:-.3pt;">Combined vitamin D and calcium and cancer</font></p>

<p style="margin-left:.5in;">

Cancer from all causes and total cancer mortality</p>

<p style="margin-left:.5in;">

Colorectal adenoma</p>

<p style="margin-left:.45in;">

Breast cancer</p>

<p style="margin-left:.3in;">

Combined vitamin D and calcium and pregnancy-related outcomes</p>

<p style="margin-left:.45in;">

<font style="letter-spacing:0pt;">Preeclampsia</font></p>

<p style="margin-left:.5in;">

Other pregnancy-related outcomes</p>

<p style="margin-left:.3in;">

Combined vitamin D and calcium and clinical outcomes of bone health</p>

<p style="margin-left:.45in;">

Rickets, fractures, falls, or performance measures</p>

<p style="margin-left:.3in;">

Combined vitamin D and calcium and all-cause mortality</p>

<p style="margin-left:.3in;">

<font style="letter-spacing:-.3pt;">Combined vitamin D and calcium and hypertension and blood pressure</font></p>

<p style="margin-left:.5in;">

Combined vitamin D and calcium and hypertension</p>

<p style="margin-left:.5in;">

<font style="letter-spacing:-.3pt;">Combined vitamin D and calcium and blood pressure</font></p>

<p style="text-indent:.15in;margin-left:.15in;margin-right:.05in;">

<font style="letter-spacing:-.4pt;">Combined vitamin D and calcium and bone mineral density or bone mineral content</font><font style="letter-spacing:-.4pt;"><b> </b></font>How does dietary intake of vitamin D from fortified foods and vitamin D supplementation affect serum 25(OH)D concentrations (arrow 4)?</p>

<p style="margin-left:.3in;margin-right:.35in;margin-top:1.8pt;">

<font style="letter-spacing:-.4pt;">RCTs on dietary intakes of vitamin D from fortified foods and serum 25(OH)D </font>concentrations</p>

<p style="margin-left:.3in;">

<font style="letter-spacing:-.3pt;">RCTs on vitamin D supplementation and serum 25(OH)D concentrations</font></p>

<p style="margin-left:.15in;">

Outcomes for Tolerable Upper Intake Levels</p>

<p style="margin-left:.3in;">

Renal outcomes</p>

<p style="margin-left:.3in;">

Adverse events reported in RCTs</p>

<p style="margin-top:14.4pt;">

Chapter 4. Discussion</p>

<p style="margin-left:.15in;">

Strengths of this report</p>

<p style="margin-left:.15in;">

DRI and the literature on vitamin D and calcium</p>

<p style="margin-left:.15in;">

Limitations of our methodological approach</p>

<p style="margin-left:.15in;">

Comments on the observational studies</p>

<p style="margin-left:.15in;">

Sources of heterogeneity and potential biases</p>

<p style="text-indent:.15in;margin-left:.15in;margin-right:1.35in;">

<font style="letter-spacing:-.5pt;">Vitamin D intake and response in serum 25(OH)D concentration</font><font style="letter-spacing:-.5pt;"><b> </b></font><font style="letter-spacing:-.3pt;">Considerations for future DRI committees</font></p>

<p>

<font style="letter-spacing:-.3pt;"><font style="letter-spacing:0pt;"> </font></font></p>

<p>

<font style="letter-spacing:-.4pt;">Latitudes of selected cities</font></p>

<p>

<font style="letter-spacing:-.4pt;"><font style="letter-spacing:0pt;"> </font></font></p>

<p>

<b>Tables</b></p>

<p style="margin-top:10.8pt;">

Table 1. Number of primary studies on vitamin D intake or concentration and specific</p>

<p style="margin-left:.35in;">

health outcomes that could be applicable to certain life stages</p>

<p>

Table 2. Number of primary studies on calcium intake and specific health outcomes that</p>

<p style="margin-left:.35in;">

could be applicable to certain life stages</p>

<p>

Table 3. Number of primary studies on combined vitamin D and calcium intake and</p>

<p style="margin-left:.35in;">

specific health outcomes that are relevant to certain life stages</p>

<p style="margin-right:.65in;">

<font style="letter-spacing:-.4pt;">Table 4. Vitamin D on growth outcome: Characteristics of interventional studies</font><font style="letter-spacing:-.4pt;"><b> </b></font></p>

<p style="margin-right:.65in;">

<font style="letter-spacing:-.1pt;">Table 5. Vitamin D and growth outcomes: Characteristics of cohort studies</font><font style="letter-spacing:-.1pt;"> </font></p>

<p style="margin-right:.65in;">

<font style="letter-spacing:-.3pt;">Table 6. Vitamin D and growth outcomes: Results of RCTs</font></p>

<p>

Table 7. Vitamin D and growth outcomes: Results of cohort studies</p>

<p style="margin-right:1.05in;">

<font style="letter-spacing:-.5pt;">Table 8. Vitamin D and cardiovascular outcomes: Characteristics of RCTs</font><font style="letter-spacing:-.5pt;"><b> </b></font></p>

<p style="margin-right:1.05in;">

Table 9. Vitamin D and cardiovascular outcomes: Results of RCTs</p>

<p style="margin-right:.4in;margin-top:3.6pt;">

<font style="letter-spacing:-.4pt;">Table 10. Vitamin D and cardiovascular outcomes: Characteristics of cohort studies</font><font style="letter-spacing:-.4pt;"><b> </b></font></p>

<p style="margin-right:.4in;margin-top:3.6pt;">

Table 11. Vitamin D and cardiovascular outcomes: Results of cohort studies</p>

<p style="margin-right:2.15in;">

<font style="letter-spacing:-.5pt;">Table 12. Vitamin D and weight: Characteristics of RCTs </font></p>

<p style="margin-right:2.15in;">

Table 13. Vitamin D and weight: Results of RCTs</p>

<p>

<font style="letter-spacing:-.4pt;">Table 15. Vitamin D and total cancer: Characteristics of cohort studies</font><font style="letter-spacing:-.4pt;"> </font></p>

<p style="margin-right:1.3in;margin-top:1.8pt;">

Table 16. Vitamin D and total cancer: Results of RCTs</p>

<p>

Table 17. Vitamin D and total cancer: Results of cohort studies</p>

<p style="margin-right:.2in;">

<font style="letter-spacing:-.4pt;">Table 18. Vitamin D and prostate cancer: Characteristics of nested case-control studies</font><font style="letter-spacing:-.4pt;"><b> </b></font></p>

<p style="margin-right:.2in;">

Table 19. Vitamin D and prostate cancer: Results of nested case-control studies</p>

<p style="margin-right:1.45in;">

<font style="letter-spacing:-.4pt;">Table 20. Vitamin D and colorectal cancer: Characteristics of RCTs</font><font style="letter-spacing:-.4pt;"><b> </b></font></p>

<p style="margin-right:1.45in;">

Table 21. Vitamin D and colorectal cancer: Results of RCTs</p>

<p style="margin-right:.35in;">

<font style="letter-spacing:-.4pt;">Table 22. Vitamin D and colorectal cancer: Characteristics of observational studies</font><font style="letter-spacing:-.4pt;"><sup><font style="font-size:9.6pt;">A</font></sup></font><font style="letter-spacing:-.4pt;"><b> </b></font></p>

<p style="margin-right:.35in;">

Table 23. Vitamin D and colorectal cancer: Results of observational studies</p>

<p style="margin-right:.3in;margin-top:3.6pt;">

<font style="letter-spacing:-.4pt;">Table 24. Vitamin D and colorectal adenoma: Characteristics of observational studies</font><font style="letter-spacing:-.4pt;"><b> </b></font></p>

<p style="margin-right:.3in;margin-top:3.6pt;">

Table 25. Vitamin D and colorectal adenoma: Results of observational studies</p>

<p style="margin-right:.7in;margin-top:1.8pt;">

<font style="letter-spacing:-.4pt;">Table 26. Vitamin D and breast cancer: Characteristics of observational studies</font><font style="letter-spacing:-.4pt;"><b> </b></font></p>

<p style="margin-right:.7in;margin-top:1.8pt;">

Table 27. Vitamin D and breast cancer: Results of observational studies</p>

<p style="margin-right:.4in;">

<font style="letter-spacing:-.3pt;">Table 28. Vitamin D and pancreatic cancer: Characteristics of observational studies</font><font style="letter-spacing:-.3pt;"><b> </b></font></p>

<p style="margin-right:.4in;">

Table 29. Vitamin D and pancreatic cancer: Results of observational studies</p>

<p>

Table 30. Vitamin D (mother) and immunologic outcomes (offspring): Characteristics of cohort studies</p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.1in;">

<font style="letter-spacing:-.4pt;">Table 31. Vitamin D (mother) and immunologic outcomes (offspring): Results of cohort </font><font style="letter-spacing:0pt;">studies</font></p>

<p style="margin-right:.3in;">

<font style="letter-spacing:-.4pt;">Table 32. Vitamin D and preeclampsia: Characteristics of nested case-control studies</font><font style="letter-spacing:-.4pt;"> </font></p>

<p style="margin-right:.3in;">

Table 33. Vitamin D and preeclampsia: Results of nested case-control studies</p>

<p>

Table 34. Summary of systematic review of the effect of vitamin D on bone health</p>

<p>

<font style="letter-spacing:-.3pt;">Table 35. Vitamin D and bone health: Characteristics of RCTs published after the Ottawa </font><font style="letter-spacing:0pt;">EPC report</font></p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.2in;">

<font style="letter-spacing:-.4pt;">Table 36. Vitamin D and bone health: Results of RCTs published after the Ottawa EPC </font><font style="letter-spacing:0pt;">report</font></p>

<p>

<font style="letter-spacing:0pt;"><font style="letter-spacing:0pt;"> </font></font></p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.25in;">

<font style="letter-spacing:-.5pt;">Table 37. Summary of systematic review on vitamin D supplementation and all-cause </font><font style="letter-spacing:0pt;">mortality</font></p>

<p style="margin-right:.8in;">

<font style="letter-spacing:-.4pt;">Table 38. Vitamin D and all-cause mortality: Characteristics of cohort studies</font><font style="letter-spacing:-.4pt;"><b> </b></font></p>

<p style="margin-right:.8in;">

Table 39. Vitamin D and all-cause mortality: Results of cohort studies</p>

<p>

Table 40. Vitamin D and hypertension: Characteristics of cohort studies</p>

<p style="margin-right:.1in;">

<font style="letter-spacing:-.4pt;">Table 41. Vitamin D and hypertension: Results of cohort and nested case control studies</font><font style="letter-spacing:-.4pt;"><b> </b></font></p>

<p style="margin-right:.1in;">

Table 42. Vitamin D and blood pressure: Characteristics of RCTs</p>

<p>

Table 43. Vitamin D and blood pressure: Results of RCTs</p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.15in;">

<font style="letter-spacing:-.3pt;">Table 44. Vitamin D and bone mineral density: Characteristics of RCTs published after </font>the Ottawa EPC report</p>

<p style="text-indent:-.35in;margin-left:.35in;">

<font style="letter-spacing:-.5pt;">Table 45. Vitamin D and bone mineral density or bone mineral contents: Results of RCTs </font><font style="letter-spacing:-.3pt;">published after the Ottawa EPC report</font></p>

<p style="margin-right:1in;">

<font style="letter-spacing:-.4pt;">Table 46. Summary of systematic review of calcium on growth in children</font><font style="letter-spacing:-.4pt;"> </font></p>

<p style="margin-right:1in;">

Table 47. Calcium and growth: Characteristics of primary studies</p>

<p>

Table 48. Calcium and growth: Results of primary studies</p>

<p style="margin-right:.5in;">

<font style="letter-spacing:-.4pt;">Table 49. Calcium and cardiovascular outcomes: Characteristics of cohort studies</font><font style="letter-spacing:-.4pt;"><sup><font style="font-size:9.6pt;">B</font></sup></font><font style="font-size:3pt;letter-spacing:-.4pt;"> </font></p>

<p style="margin-right:.5in;">

Table 50. Calcium and cardiovascular outcomes: Results of cohort studies</p>

<p style="margin-right:1.3in;">

<font style="letter-spacing:-.4pt;">Table 51. Systematic reviews of calcium supplementation and weight</font><font style="letter-spacing:-.4pt;"><b> </b></font></p>

<p style="margin-right:1.3in;">

Table 52. Calcium and weight: Characteristics of RCTs</p>

<p>

Table 53. Calcium and weight: Results of RCTs</p>

<p>

Table 54. Calcium and total cancer mortality: Characteristics of RCTs</p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.4in;">

<font style="letter-spacing:-.4pt;">Table 55. Calcium and total cancer incidence or mortality: Characteristics of cohort </font><font style="letter-spacing:0pt;">studies</font></p>

<p>

Table 56. Calcium and total cancer mortality: Results of RCTs</p>

<p style="margin-right:.4in;">

<font style="letter-spacing:-.3pt;">Table 57. Calcium and total cancer incidence or mortality: Results of cohort studies</font><font style="letter-spacing:-.3pt;"> </font><font style="letter-spacing:-.3pt;">50-71, males</font></p>

<p style="margin-right:.7in;">

<font style="letter-spacing:-.4pt;">Table 58. Calcium and prostate cancer: Characteristics of observational studies</font><font style="letter-spacing:-.4pt;"><b> </b></font></p>

<p style="margin-right:.7in;">

Table 59. Calcium and prostate cancer: Results of observational studies</p>

<p>

<font style="letter-spacing:-.3pt;">Table 60. Systematic review of calcium supplementation and colorectal cancer incidence </font>or adenoma recurrence</p>

<p style="margin-right:.6in;margin-top:1.8pt;">

<font style="letter-spacing:-.4pt;">Table 61. Calcium and colorectal cancer: Characteristics of observational studies</font><font style="letter-spacing:-.4pt;"><b> </b></font></p>

<p style="margin-right:.6in;margin-top:1.8pt;">

Table 62. Calcium and colorectal cancer: Results of cohort studies</p>

<p style="margin-right:.4in;margin-top:3.6pt;">

<font style="letter-spacing:-.1pt;">Table 63. Calcium and colorectal cancer: Results of nested case-control studies</font><font style="letter-spacing:-.1pt;"><b> </b></font></p>

<p style="margin-right:.4in;margin-top:3.6pt;">

<font style="letter-spacing:-.4pt;">Table 64. Calcium and colorectal adenoma: Characteristics of interventional studies</font><font style="letter-spacing:-.4pt;"> </font></p>

<p style="margin-right:.4in;margin-top:3.6pt;">

Table 65. Calcium and colorectal adenoma: Characteristics of cohort studies</p>

<p>

Table 66. Calcium and colorectal adenoma recurrence: Results of RCTs</p>

<p>

Table 67. Calcium and colorectal adenoma recurrence: Results of nonrandomized comparative study</p>

<p>

Table 68. Calcium and colorectal adenoma: Results of cohort studies</p>

<p style="margin-right:1.3in;margin-top:3.6pt;">

<font style="letter-spacing:-.4pt;">Table 69. Calcium and breast cancer: Characteristics of cohort studies</font><font style="letter-spacing:-.4pt;"><b> </b></font></p>

<p style="margin-right:1.3in;margin-top:3.6pt;">

Table 70. Calcium and breast cancer: Results of cohort studies</p>

<p style="margin-right:.2in;">

<font style="letter-spacing:-.4pt;">Table 71. Calcium and breast mammography density: Characteristics of cohort studies</font><font style="letter-spacing:-.4pt;"> </font></p>

<p style="margin-right:.2in;">

Table 72. Calcium and breast cancer: Results of cohort studies</p>

<p style="margin-right:1.05in;">

<font style="letter-spacing:-.4pt;">Table 73. Calcium and pancreatic cancer: Characteristics of cohort studies</font><font style="letter-spacing:-.4pt;"> </font></p>

<p style="margin-right:1.05in;">

<font style="letter-spacing:-.2pt;">Table 74. Calcium and pancreatic cancer: Results of cohort studies</font></p>

<p>

<font style="letter-spacing:-.2pt;"><b><font style="letter-spacing:0pt;"> </font></b></font></p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.65in;">

<font style="letter-spacing:-.5pt;">Table 75. Summary table of systematic review on calcium supplementation and </font><font style="letter-spacing:-.2pt;">preeclampsia, small for gestational age, preterm birth</font></p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.15in;">

<font style="letter-spacing:-.4pt;">Table 76. Calcium and preeclampsia and other pregnancy outcomes: Characteristics of </font>cohort studies</p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.25in;">

<font style="letter-spacing:-.4pt;">Table 77. Calcium and preeclampsia and other pregnancy outcomes: Results of cohort </font><font style="letter-spacing:0pt;">studies</font></p>

<p>

Table 78. Calcium intake and all-cause mortality: Characteristics of cohort studies</p>

<p>

Table 79. Calcium intake and all-cause mortality: Results of cohort studies</p>

<p>

Table 80. Calcium and hypertension incidence: Characteristics of cohort studies</p>

<p>

<font style="letter-spacing:-.2pt;">Table 81. Calcium and hypertension incidence: Results of cohort studies</font></p>

<p>

Table 82. Summary of systematic reviews of calcium and blood pressure</p>

<p>

Table 83. Calcium and blood pressure: Characteristics of RCTs</p>

<p>

<font style="letter-spacing:-.2pt;">Table 84. Calcium and blood pressure: Results of RCTs</font></p>

<p>

<font style="letter-spacing:-.3pt;">Table 86. Combined vitamin D and calcium and cardiovascular outcomes: Results of </font><font style="letter-spacing:0pt;">RCTs</font></p>

<p>

Table 87. Combined vitamin D and calcium and weight: Characteristics of RCTs</p>

<p>

Table 88. Combined vitamin D and calcium and weight: Results of RCTs</p>

<p>

Table 89. Combined vitamin D and calcium and total cancer incidence: Characteristics of <font style="letter-spacing:0pt;">RCTs</font></p>

<p style="margin-right:.1in;margin-top:1.8pt;">

<font style="letter-spacing:-.4pt;">Table 90. Combined vitamin D and calcium and total cancer incidence: Results of RCTs </font><br /><font style="letter-spacing:-.2pt;">Table 91. Combined vitamin D with calcium and colorectal cancer: Characteristics of R</font><font style="letter-spacing:0pt;">CTs</font></p>

<p style="margin-right:.05in;margin-top:3.6pt;">

<font style="letter-spacing:-.2pt;">Table 92. Combined vitamin D with calcium and colorectal cancer: Results of RCTs</font><font style="letter-spacing:-.2pt;"><b> </b></font><br />

Table 93. Combined vitamin D and calcium and breast cancer outcomes: Characteristics <font style="letter-spacing:0pt;">of RCTs</font></p>

<p>

<font style="letter-spacing:-.2pt;">Table 94. Combined vitamin D and calcium and breast cancer outcomes: Results of </font><font style="letter-spacing:0pt;">RCTs</font></p>

<p style="margin-right:.15in;">

<font style="letter-spacing:-.4pt;">Table 95. Combined vitamin D and calcium and preeclampsia: Characteristics of RCTs</font><font style="letter-spacing:-.4pt;"> </font><br />

Table 96. Combined vitamin D and calcium and preeclampsia: Results of RCTs</p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.3in;">

<font style="letter-spacing:-.5pt;">Table 97. Combined vitamin D and calcium and bone health: Characteristics of RCTs </font><font style="letter-spacing:-.3pt;">published after the Ottawa EPC report</font></p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.1in;">

<font style="letter-spacing:-.4pt;">Table 98. Combined vitamin D and calcium and bone health: Results of RCTs published </font>after the Ottawa EPC report (stress fracture)</p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.05in;">

<font style="letter-spacing:-.3pt;">Table 99. Combined vitamin D and calcium and bone health: Results of RCTs published </font>after the Ottawa EPC report (performance measures)</p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.1in;">

<font style="letter-spacing:-.3pt;">Table 100. Combined vitamin D and calcium and incident hypertension: Characteristics </font><font style="letter-spacing:0pt;">of RCTs</font></p>

<p>

<font style="letter-spacing:-.2pt;">Table 101. Combined vitamin D and calcium and incident hypertension: Results of </font><font style="letter-spacing:0pt;">RCTs</font></p>

<p>

Table 102. Combined vitamin D and calcium and blood pressure: Characteristics of <font style="letter-spacing:0pt;">RCTs</font></p>

<p>

Table 103. Combined vitamin D and calcium and blood pressure: Results of RCTs</p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.65in;">

<font style="letter-spacing:-.5pt;">Table 104. Combined vitamin D and calcium and bone mineral density/content: </font>Characteristics of RCTs published after the Ottawa EPC report</p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.1in;">

<font style="letter-spacing:-.3pt;">Table 105. Combined vitamin D and calcium and bone mineral density/content: Results </font>of RCTs published after the Ottawa EPC report</p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.3in;">

<font style="letter-spacing:-.5pt;">Table 106. The relationship between vitamin D</font><font style="font-family:Arial;font-size:8pt;letter-spacing:-.5pt;"><b>3 </b></font><font style="letter-spacing:-.5pt;">daily doses and changes in 25(OH)D </font>concentrations in RCTs</p>

<p>

<font style="letter-spacing:-.3pt;">Table 107. Adverse events reported in RCTs</font></p>

<p style="margin-top:12.6pt;">

<font style="font-family:Arial;font-size:16pt;letter-spacing:0pt;"><b>Figures</b></font></p>

<p style="margin-top:10.8pt;">

Figure 1. Summary of the vitamin D endocrine system</p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.45in;">

<font style="letter-spacing:-.5pt;">Figure 2. Generic analytic framework to assist formulation of key questions for the </font><font style="letter-spacing:-.3pt;">development of DRIs</font></p>

<p style="margin-right:1.6in;">

<font style="letter-spacing:-.5pt;">Figure 3. Analytic framework for vitamin D and/or calcium EARs</font><font style="letter-spacing:-.5pt;"><b> </b></font><br /><font style="letter-spacing:-.4pt;">Figure 4. Analytic framework for vitamin D and/or calcium ULs</font><font style="letter-spacing:-.4pt;"><b> </b></font><br />

Figure 5. Literature flow in this report</p>

<p style="margin-top:1.8pt;">

Figure 6. Cardiovascular outcomes risk stratified by vitamin D concentration</p>

<p style="margin-right:1.4in;">

<font style="letter-spacing:-.3pt;">Figure 7. Prostate cancer risk stratified by vitamin D concentration</font><font style="letter-spacing:-.3pt;"> </font><font style="letter-spacing:-.5pt;">F<br />

igure 8. Colorectal cancer risk stratified by vitamin D concentration</font><font style="letter-spacing:-.5pt;"> </font><br /><font style="letter-spacing:-.2pt;">Figure 9. Colon cancer risk stratified by vitamin D concentration</font><font style="letter-spacing:-.2pt;"><b> </b></font><br /><font style="letter-spacing:-.3pt;">Figure 10. Rectal cancer risk stratified by vitamin D concentration</font><font style="letter-spacing:-.3pt;"><b> </b></font><br /><font style="letter-spacing:-.4pt;">Figure 11. Cardiovascular outcomes risk stratified by calcium intake </font><br />

Figure 12. Stroke risk stratified by calcium intake</p>

<p>

Figure 13. Prostate cancer risk stratified by calcium intake</p>

<p>

Figure 14 Colorectal cancer risk in both sexes stratified by calcium intake</p>

<p style="margin-right:1.3in;">

<font style="letter-spacing:-.3pt;">Figure 15 Colorectal cancer risk in men stratified by calcium intake</font><font style="letter-spacing:-.3pt;"><b> </b></font><br /><font style="letter-spacing:-.5pt;">Figure 16 Colorectal cancer risk in women stratified by calcium intake </font><br />

Figure 17 Colon cancer risk stratified by calcium intake</p>

<p>

Figure 18. Rectal cancer risk stratified by calcium intake</p>

<p>

Figure 19. Colorectal adenomatous polyp risk stratified by calcium intake</p>

<p style="margin-right:.1in;text-align:justify;">

<font style="letter-spacing:.1pt;">Figure 20. Breast cancer risk stratified by calcium intake</font><font style="letter-spacing:.1pt;"> </font></p>

<p style="margin-right:.1in;text-align:justify;">

<font style="letter-spacing:.1pt;">Figure 21. Hypertension risk stratified by calcium intake</font><font style="letter-spacing:.1pt;"> </font></p>

<p style="margin-right:.1in;text-align:justify;">

<font style="letter-spacing:-.3pt;">Figure 22. Forest plot of trials of combined vitamin D and calcium supplementation and </font>effects on all-cause mortality</p>

<p style="text-indent:-.35in;margin-left:.35in;margin-right:.15in;">

<font style="letter-spacing:-.3pt;">Figure 23. Relationship between doses of Vitamin D3 supplementation and net changes in serum 25(OH)D concentrations in RCTs</font></p>

<p style="text-indent:-.35in;margin-left:.35in;">

<font style="letter-spacing:-.4pt;">Figure 24. Relationship between doses of Vitamin D</font><font style="font-size:7.5pt;letter-spacing:-.4pt;">3 </font><font style="letter-spacing:-.4pt;">supplementation and net changes in </font><font style="letter-spacing:-.3pt;">serum 25(OH)D concentrations in RCTs by baseline vitamin D status among adults</font></p>

<p style="text-indent:-.35in;margin-left:.35in;">

<font style="letter-spacing:-.4pt;">Figure 25. Relationship between doses of Vitamin D</font><font style="font-size:7.5pt;letter-spacing:-.4pt;">3 </font><font style="letter-spacing:-.4pt;">supplementation and net changes in </font><font style="letter-spacing:-.1pt;">serum 25(OH)D concentrations in RCTs by duration of supplementation among </font><font style="letter-spacing:0pt;">adults</font></p>

<p style="margin-top:14.4pt;">

<font style="font-family:Arial;font-size:16pt;letter-spacing:0pt;"><b>Appendixes</b></font></p>

<p style="margin-right:2.4in;margin-top:9pt;">

Appendix A. Search Strategy for Primary Studies<br /><font style="letter-spacing:-.4pt;">Appendix B. Search Strategy for Systematic Reviews </font><br />

Appendix C. Evidence Tables</p>

<p>

<font style="letter-spacing:-.3pt;">Appendix D. Existing Systematic Reviews</font></p>

<p style="margin-right:.4in;">

<font style="letter-spacing:-.5pt;">Appendix E. Blank Data Extraction Form and Quality Assessment Checklists </font><font style="letter-spacing:-.3pt;">Appendix F. Excluded Studies With Reasons</font></p>

<p style="margin-top:9pt;">

<font style="letter-spacing:-.5pt;"><b>Appendixes and Evidence Tables for this report are provided electronically at </b></font><a href="http://www.ahrq.gov/downloads/pub/evidence/pdf/vitadcal/vitadcal.pdf." style="color:rgb(0,0,255);"><font style="color:rgb(0,0,255);"><b><u>http://www.ahrq.gov/downloads/pub/evidence/pdf/vitadcal/vitadcal.pdf.</u></b></font></a></p>